Display search results for ** instead (2 products)

2 Item(s)

This Vital Signs issue discusses the Danaher's acquisition of Cepheid for nearly $4 Billion in cash, and Orphan Drug Expenditures in the United States: A Historical and Prospective Analysis, 2007–2013.

USD 600.00

USD 450.00 save 25 %

This Vital Signs issue discusses the clinical diagnostics laboratory tests payment system, approval of a Zika test kit, the impact on innovation of mergers in the pharma/biotech industry, and national healthcare expenditure projections through 2025.

USD 600.00

USD 450.00 save 25 %

2 Item(s)